Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anavex2-73
2. Tetrahydro-n, N-dimethyl-2,2-diphenyl-3-furanmethanamine Hydrochloride
1. 195615-83-9
2. Avex-73
3. Thd-dp-fm
4. Ae-37
5. Ae37
6. Blarcamesine [usan]
7. Anavex-2-73
8. 9t210mmz3f
9. Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanemethanamine
10. 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine
11. Blarcamesine (usan)
12. Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine
13. 3-furanmethanamine, Tetrahydro-n,n-dimethyl-2,2-diphenyl-
14. 1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethanamine
15. (r)-1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethanamine
16. Unii-9t210mmz3f
17. Anavex
18. Ae 37
19. Blarcamesine [inn]
20. An2/avex-73
21. Avex-73?
22. Schembl181634
23. Chembl4297224
24. Gtpl11586
25. Dtxsid60941344
26. Bcp23552
27. Ex-a3143
28. Bdbm50559171
29. Anavex-2-73 Free Base (blarcamesine)
30. Db05592
31. Sb17187
32. Ncgc00387227-01
33. Ac-35490
34. Hy-105296
35. Cs-0025655
36. D11383
37. D87137
38. Q25110485
39. Rac-1-((3r)-2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine
| Molecular Weight | 281.4 g/mol |
|---|---|
| Molecular Formula | C19H23NO |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | 281.177964357 g/mol |
| Monoisotopic Mass | 281.177964357 g/mol |
| Topological Polar Surface Area | 12.5 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 298 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in breast cancer.
Drugs in Development
Details:
ANAVEX2-73 (blarcamesine) is an oral drug that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for treating Alzheimer's disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Brand Name: ANAVEX2-73
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 13, 2025
Lead Product(s) : Blarcamesine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Blarcamesine Data Shows Benefits for Alzheimer’s Disease in 3-Year Treatment
Details : ANAVEX2-73 (blarcamesine) is an oral drug that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for treating Alzheimer's disease.
Product Name : ANAVEX2-73
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2025
Details:
ANAVEX2-73 (blarcamesine) is an oral drug that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for treating Alzheimer's disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2024
Lead Product(s) : Blarcamesine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
Details : ANAVEX2-73 (blarcamesine) is an oral drug that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for treating Alzheimer's disease.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 23, 2024
Details:
ANAVEX2-73 (blarcamesine) is an oral drug that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for treating Alzheimer's disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Brand Name: ANAVEX2-73
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 26, 2024
Lead Product(s) : Blarcamesine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Anavex Submits Blarcamesine MAA to EMA for Alzheimer’s Disease Treatment
Details : ANAVEX2-73 (blarcamesine) is an oral drug that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for treating Alzheimer's disease.
Product Name : ANAVEX2-73
Product Type : Small molecule
Upfront Cash : Not Applicable
November 26, 2024
Details:
ANAVEX2-73 (blarcamesine) is an oral drug that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for treating Alzheimer's disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Brand Name: ANAVEX2-73
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2024
Lead Product(s) : Blarcamesine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Anavex Submits Phase IIb/III Alzheimer’s Data to Peer-Reviewed Journal
Details : ANAVEX2-73 (blarcamesine) is an oral drug that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for treating Alzheimer's disease.
Product Name : ANAVEX2-73
Product Type : Small molecule
Upfront Cash : Not Applicable
November 25, 2024
Details:
ANAVEX 2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is in phase 3 development for Rett syndrome.
Lead Product(s): Blarcamesine
Therapeutic Area: Genetic Disease Brand Name: Anavex 2-73
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Lead Product(s) : Blarcamesine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Anavex Life Sciences Provides an Update on Rett Syndrome Program
Details : ANAVEX 2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is in phase 3 development for Rett syndrome.
Product Name : Anavex 2-73
Product Type : Small molecule
Upfront Cash : Not Applicable
January 02, 2024
Details:
ANAVEX 2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 3 clinical development for the treatment of patients with Rett syndrome (RTT).
Lead Product(s): Blarcamesine
Therapeutic Area: Genetic Disease Brand Name: Anavex 2-73
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Lead Product(s) : Blarcamesine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Pati...
Details : ANAVEX 2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 3 clinical development for the treatment of patients with Rett syndrome (RTT).
Product Name : Anavex 2-73
Product Type : Small molecule
Upfront Cash : Not Applicable
December 20, 2023
Details:
ANAVEX 2-73 (blarcamesine) is M1 & σ1 receptor agonist, which is being evaluated in phase 2/3 clinical trials for the treatment of Alzheimer’s Disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Brand Name: ANAVEX 2-73
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Lead Product(s) : Blarcamesine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ANAVEX 2-73 (blarcamesine) is M1 & σ1 receptor agonist, which is being evaluated in phase 2/3 clinical trials for the treatment of Alzheimer’s Disease.
Product Name : ANAVEX 2-73
Product Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2023
Details:
ANAVEX2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for the treatment of Alzheimer's disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Brand Name: ANAVEX2-73
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Lead Product(s) : Blarcamesine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ANAVEX2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for the treatment of Alzheimer's disease.
Product Name : ANAVEX2-73
Product Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2023
Details:
ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is being investigated for alzheimer’s disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Brand Name: Anavex 2-73
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Lead Product(s) : Blarcamesine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease ...
Details : ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is being investigated for alzheimer’s disease.
Product Name : Anavex 2-73
Product Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2023
Details:
ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is being investigated for rett syndrome.
Lead Product(s): Blarcamesine
Therapeutic Area: Genetic Disease Brand Name: Anavex 2-73
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Lead Product(s) : Blarcamesine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEXÂ2-73 (blarcamesine) for...
Details : ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is being investigated for rett syndrome.
Product Name : Anavex 2-73
Product Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
91
PharmaCompass offers a list of Blarcamesine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Blarcamesine manufacturer or Blarcamesine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Blarcamesine manufacturer or Blarcamesine supplier.
PharmaCompass also assists you with knowing the Blarcamesine API Price utilized in the formulation of products. Blarcamesine API Price is not always fixed or binding as the Blarcamesine Price is obtained through a variety of data sources. The Blarcamesine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Blarcamesine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Blarcamesine, including repackagers and relabelers. The FDA regulates Blarcamesine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Blarcamesine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Blarcamesine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Blarcamesine supplier is an individual or a company that provides Blarcamesine active pharmaceutical ingredient (API) or Blarcamesine finished formulations upon request. The Blarcamesine suppliers may include Blarcamesine API manufacturers, exporters, distributors and traders.
click here to find a list of Blarcamesine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Blarcamesine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Blarcamesine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Blarcamesine GMP manufacturer or Blarcamesine GMP API supplier for your needs.
A Blarcamesine CoA (Certificate of Analysis) is a formal document that attests to Blarcamesine's compliance with Blarcamesine specifications and serves as a tool for batch-level quality control.
Blarcamesine CoA mostly includes findings from lab analyses of a specific batch. For each Blarcamesine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Blarcamesine may be tested according to a variety of international standards, such as European Pharmacopoeia (Blarcamesine EP), Blarcamesine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Blarcamesine USP).
